Matsupexole (KDT-3594) vs Piribedil (Clarium)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: D2/D3 · full Parkinson's Disease pipeline

Matsupexole (KDT-3594)

Developed by Kissei Pharmaceutical

Phase 2 in Parkinson's Diseasesmall molecule
Partial signal

NCT03845387 · Phase 2 · completed

The study randomly assigned 74 participants to KDT-3594 or active treatment with pramipexole, but neither participants nor investigators were blinded. Its primary endpoint was the clinical MDS-UPDRS score at 12 weeks; because no results or statistical comparison are posted, whether this endpoint was met is unknown.

No aligned efficacy figure on record for this race.

Piribedil (Clarium)

Marketed by Desitin Arzneimittel GmbH

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT01007864 · Phase 3 · completed

The trial randomized patients to piribedil or an active comparator, but only the outcomes assessor (not patients or investigators) was blinded, and the primary vigilance test showed no significant difference between piribedil and the comparator drugs.

Reported efficacy

The primary efficacy variable will be the 'median reaction time during the second 15 minutes (minutes 16-30)' of the subtest 'vigilance', visual test condition 'moving bar', of the Test battery for Attention Performances (TAP) at end of treatment. (Baseline and End of Treatment): Primary endpoint (median reaction time, TAP battery vigilance subtest, minutes 16-30, end of treatment): piribedil 996 ms vs comparator (pramipexole/ropinirole) 954 ms; P=0.68 - no significant difference. (missed)

Result source: NCT01007864

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMatsupexole (KDT-3594)Piribedil (Clarium)
OFF time, change—Not reported—Not posted · NCT01007864
ON time without troublesome dyskinesia, change—Not reported—Not posted · NCT01007864
UPDRS Part III, change—Not reported—Not posted · NCT01007864
MDS-UPDRS Part II, change—Not reported—Not posted · NCT01007864

OFF time, change

Matsupexole (KDT-3594)
—Not reported
Piribedil (Clarium)
—Not posted · NCT01007864

ON time without troublesome dyskinesia, change

Matsupexole (KDT-3594)
—Not reported
Piribedil (Clarium)
—Not posted · NCT01007864

UPDRS Part III, change

Matsupexole (KDT-3594)
—Not reported
Piribedil (Clarium)
—Not posted · NCT01007864

MDS-UPDRS Part II, change

Matsupexole (KDT-3594)
—Not reported
Piribedil (Clarium)
—Not posted · NCT01007864
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Matsupexole (KDT-3594): no structured comparison results are available for Parkinson's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Piribedil (Clarium)
Primary endpoint (median reaction time, TAP battery vigilance subtest, minutes 16-30, end of treatment): piribedil 996 ms vs comparator (pramipexole/ropinirole) 954 ms; P=0.68 - no significant difference. NCT01007864 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Matsupexole (KDT-3594)'s landscape · Piribedil (Clarium)'s landscape